Lucentis wins final FDA nod for diabetics; KV wins Medicaid coverage for Makena;

 @FiercePharma: "Unnerved" by "weakness in the base business," Jefferies downgrades Glaxo to "hold." Next year = better, firm says. More | Follow @FiercePharma

> The FDA gave its blessing to broader use of Roche's ($RHHBY) eye drug Lucentis in patients with diabetic macular edema. Report

> KV Pharmaceutical got a boost in court when a judge ordered Georgia's Medicaid program to cover the pricey treatment for premature birth; partly because of Makena's stumbles, KV is now in bankruptcy. Report

> GlaxoSmithKline ($GSK) was downgraded by Jefferies after the drugmaker said its margins wouldn't increase as planned this year, thanks to pricing pressures. Report

> Patients at risk of diabetes do see that risk increased with the use of cholesterol-lowering statins, but the cardiovascular benefits of those drugs still outweigh that risk, a Lancet study found. Report

> Ranbaxy Laboratories has moved production of its Lipitor copy to a new plant in Mohali, India, from the U.S. Report

> Express Scripts plans to divest or dissolve some businesses, including a diabetes supply business, a joint venture in China and its business in Germany and France. Report

> India's Cipla plans to revamp its business in China to focus on manufacturing biosimilars and active pharmaceutical ingredients. Report

Medical Device News

 @FierceMedDev: Given Imaging's rough stock slump last week was a major overreaction, at least one analyst is saying--via Bloomberg. More | Follow @FierceMedDev

 @MarkHFierce: MIT tech helped U.K. scientists discover a new class of polymers that could coat med devices and help reduce bacteria. Story | Follow @MarkHFierce

 @DamianFierce: Medtronic is looking to get a foothold in China with some M&A. More | Follow @DamianFierce

> U.K. researchers wield MIT tech to discover new class of antimicrobial polymers. Item

> FDA clears Stryker's next-gen stroke treatment device. News

Biotech News

 @FierceBiotech: FDA taps data-mining tech for drug safety research. More | Follow @FierceBiotech

 @JohnCFierce: Elcelyx sheds stealth status, adds venture bucks as it seeks obesity pacts. More | Follow @JohnCFierce

 @RyanMFierce: Mount Sinai's Eric Schadt reflects on first year at $100 million genomics center. More | Follow @RyanMFierce

> Both low and OK'd doses of Acorda's Ampyra fall shy of key endpoint. Article

> Elan stokes buyout buzz with plan for $130M R&D spinout. News

> Elcelyx sheds stealth status, adds venture bucks as it seeks obesity pacts. News

Biotech IT News

> BioClinica accelerates spending to support eClinical surge. Article

> Sanofi trains social-media eye on diabetics. Story

> U.K. scientists tap into e-health research with Centers of Excellence. More

CRO News

> Theorem and Gallus team up to offer CRO, CMO services. Article

> Charles River bolsters IT spending to stand out in CRO crowd. Story

> Fuji Pharma jumps into CMO game with $53.4M plant buy. More

And Finally... Daily aspirin may protect against cancer, but perhaps not as much as previously thought. Report